文献速递骨显像与常规 SPECT核素与放射性配体治疗

223Ra治疗晚期转移性去势抵抗性前列腺癌:骨骼肿瘤负荷定量评估用于预后判断临床结局与血液学毒性

223Ra Therapy of Advanced Metastatic Castration-Resistant Prostate Cancer: Quantitative Assessment of Skeletal Tumor Burden for Prognostication of Clinical Outcome and Hematologic Toxicity.
PubMed 文献 · J Nucl Med · 2017-09-01

该回顾性研究纳入88例接受223RaCl2治疗的晚期转移性去势抵抗性前列腺癌(mCRPC)患者,评估骨扫描指数(BSI)对总生存(OS)和血液学毒性的预后价值。多因素分析显示,基线BSI>5与OS缩短(中位OS 8.2个月 vs ≤5组15.0个月;HR 2.65,95%CI 1.5-4.71;P=0.001)及血液学毒性风险升高(OR 3.02,95%CI 1.2-7.8;P=0.02)显著相关。BSI在治疗期间的变化与OS无显著关联。

要点

  • 基线BSI>5的mCRPC患者接受223RaCl2治疗中位OS为8.2个月,≤5者为15.0个月(HR 2.65;P=0.001)。
  • 基线BSI>5与血液学毒性(2-5级)发生风险升高相关(OR 3.02;95%CI 1.2-7.8;P=0.02)。
  • 完成3周期治疗者中44%(n=52)BSI下降,治疗结束时84%(n=32)BSI下降,但BSI变化与OS无显著关联。

核心结论

  • BSI是晚期mCRPC患者接受223RaCl2治疗时预后判断OS和血液学毒性的有前景的生物标志物。
  • 需要进一步的前瞻性研究来评估BSI用于223RaCl2治疗反应评估的潜力。

研究设计与样本

  • 该研究为回顾性研究,纳入丹麦队列中2014年3月至2015年10月期间接受223RaCl2治疗且具有基线骨扫描的mCRPC患者。
  • 共纳入88例患者;骨扫描研究按疾病范围分级,并通过自动化BSI(EXINI BoneBSI)对基线、3周期后随访及治疗结束时的扫描进行定量。
  • 临床结局为OS和2-5级血液学毒性的发生;在多变量回归模型中分析BSI与临床结局的关联,模型包括骨扫描视觉评估和其他相关协变量。

主要发现

  • 完成223RaCl2周期的中位数为4,27例(31%)完成了6周期。
  • 多因素分析显示BSI与OS显著相关;BSI>5组中位OS为8.2个月,BSI≤5组中位OS为15.0个月(HR 2.65;95%CI 1.5-4.71;P=0.001)。
  • 基线BSI对血液学毒性发生具有预后价值;BSI>5组发生毒性的OR为3.02(95%CI 1.2-7.8;P=0.02)。
  • 完成3周期223RaCl2治疗的患者(n=52)中44%出现BSI下降,治疗结束后的患者(n=32)中84%出现BSI下降。
  • 治疗期间BSI变化与OS之间无显著关联。

关键数值与推荐

  • BSI>5组中位OS为8.2个月,BSI≤5组中位OS为15.0个月(HR 2.65;95%CI 1.5-4.71;P=0.001)。
  • BSI>5组血液学毒性OR为3.02(95%CI 1.2-7.8;P=0.02)。
  • 完成3周期治疗者(n=52)中44% BSI下降;治疗结束者(n=32)中84% BSI下降。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需要进一步的前瞻性研究来评估BSI用于223RaCl2治疗反应评估的潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this study was to investigate the prognostic value of the quantitative assessment of skeletal tumor burden on bone scintigraphy (Bone Scan Index [BSI]) in patients who have advanced metastatic castration-resistant prostate cancer (mCRPC) and are receiving 223RaCl2 We hypothesized that the BSI can serve as a prognostic biomarker of overall survival (OS) and hematologic toxicity and as a tool for response assessment in patients with mCRPC treated with 223RaCl2Methods: This study was a retrospective investigation of a Danish cohort of mCRPC patients who received 223RaCl2 therapy between March 2014 and October 2015 and for whom baseline bone scintigraphy was available. Bone scintigraphy studies were reviewed and graded according to the extent of disease. Furthermore, an automated BSI (EXINI BoneBSI) was obtained for baseline scintigraphy studies and follow-up scans after 3 cycles as well as at the end of therapy. Clinical outcomes were OS and occurrence of hematologic toxicity of grades 2-5. Associations between the BSI and clinical outcomes were investigated in multivariate regression models including the visual assessment of bone scintigraphy and other relevant covariates. Results: A total of 88 patients were included. The median number of completed 223RaCl2 cycles was 4, and 27 patients (31%) completed 6 cycles. The BSI was significantly associated with OS in the multivariate analysis; the median OS for patients with a BSI of greater than 5 was 8.2 mo, and the median OS for patients with a BSI of less than or equal to 5 was 15.0 mo (hazard ratio, 2.65 [95% confidence interval, 1.5-4.71]; P = 0.001). Likewise, the baseline BSI was prognostic for the occurrence of hematologic toxicity; patients with a BSI of greater than 5 had an odds ratio of 3.02 (95% confidence interval, 1.2-7.8; P = 0.02) for toxicity. The BSI declined during therapy in 44% of the patients who completed 3 cycles of 223RaCl2 (n = 52) and in 84% of the patients after the end of therapy (n = 32). There was no significant association between a change in the BSI during therapy and OS. Conclusion: The BSI is a promising biomarker for prognostication of OS and hematologic toxicity in late-stage mCRPC patients receiving 223RaCl2 Further prospective studies are needed to evaluate the potential of the BSI for response assessment in 223RaCl2 therapy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Fosbøl MØ, Petersen PM, Kjaer A, et al. 223Ra Therapy of Advanced Metastatic Castration-Resistant Prostate Cancer: Quantitative Assessment of Skeletal Tumor Burden for Prognostication of Clinical Outcome and Hematologic Toxicity. J Nucl Med. 2017. PMID: 28864632. doi:10.2967/jnumed.117.195677

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。